A Facile Synthesis and Discovery of Highly Functionalized Tetrahydro-pyridines and Pyridines as Antimycobacterial Agents

Suresh Kumar RAJU,^a Michael Rajesh STEPHEN,^a Perumal SUBBU,*^a Banerjee DEBJANI,^b Yogeeswari PERUMAL,^b and Sriram DHARMARAJAN^b

^aDepartment of Organic Chemistry, School of Chemistry, Madurai Kamaraj University; Madurai 625021, India; and

^bMedicinal Chemistry & Antimycobacterial Research Laboratory, Pharmacy Group, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad-500 078, Andhra Pradesh, India.

Received August 17, 2009; accepted January 28, 2010; published online February 3, 2010

The four-component reaction of ethyl 3-oxo-4-(arylsulfanyl)butanoate, substituted aromatic aldehydes and ammonium acetate afforded novel ethyl 4-hydroxy-2,6-diaryl-5-(arylsulfanyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylates. These tetrahydro-pyridine esters upon dehydrogenation with dichlorodicyanobenzoquinone (DDQ) afforded highly functionalized pyridines in excellent yields. These novel heterocycles were screened for their *in vitro* activity against *Mycobacterium tuberculosis* H37Rv using agar dilution method. Among the compounds screened, ethyl 2,6-di(2-bromophenyl)-4-hydroxy-5-(phenylsulfanyl)-3-pyridinecarboxylate was found to be the most active with a minimum inhibitory concentration of 1.33 μM against *Mycobacterium tuberculosis* and is 5.74 and 38.17 times more potent than the first line anti-tuberculosis (TB) drugs, ethambutol and pyrazinamide respectively.

Key words pyridinecarboxylate; Mannich reaction; stereochemistry; *Mycobacterium tuberculosis*

Piperidones serve an important role as intermediates to substituted piperidines^{1–3} and they are found to be a part of more complex biologically active compounds.⁴ Apart from possessing analgesic,^{5,6} anti-inflammatory,⁵ central nervous system (CNS) depressant,^{7,8} local anesthetic,^{7,9} anticancer,¹⁰ and antimicrobial activities,¹¹ piperidones are valuable synthetic intermediates for the preparation of various alkaloids and pharmaceuticals.^{12–14} Piperidones have also been used as key chiral intermediates in the preparation of a large number of natural and synthetic compounds with significant anticancer,¹⁵ anti human immunodeficiency virus (HIV)¹⁶ and glycosidase inhibition¹⁷ activities. Tetrahydropyridine derivatives are useful against several metabolic disorders and human ailments and are involved in monoamine oxidase based mechanism in Parkinson's disease^{18,19} and as inhibitors of farnesyl transferase²⁰ and dihydroorate dehydrogenase²¹ and also play key roles in many disease processes.

The pyridine motif is found in various therapeutic agents, including numerous antihistamines,²² antiseptic,²³ antiarrhythmic,²⁴ antirheumatic,²⁵ and other pharmaceutical agents and natural products. They also play a pivotal role in catalyzing both biological and chemical reactions.²⁶ Highly functionalized pyridines, including aryl- and heteroaryl-substituted derivatives, are widespread in the pharmaceutical and agrochemical sectors.^{27,28} Due to their π -stacking ability, some pyridines are used in supramolecular chemistry as well.^{29,30} Hence the synthesis of polysubstituted piperidones and pyridines is a topic of current interest.^{31,32} This prompted us to perform the synthesis of poly substituted piperidines and pyridines and probe their biological potential.

It is pertinent to note that tuberculosis (TB) remains one of the major causes of disability and death worldwide. The WHO Global TB report released in March 2009³³ shows that in 2007 there were an estimated 1.4 million new cases of tuberculosis among HIV-infected people and 456000 deaths. In addition, the number of people contracting TB is on the rise, as their immune systems are impaired by immunosuppressive

drugs or substance abuse or HIV/AIDS. The emergence of multi-drug resistant TB (MDR-TB), defined as resistance to at least isoniazid and rifampicin, and the extensively drug resistant (XDR-TB) strains also impedes the discovery and the development of new drugs.^{34,35} In the last 50 years, only a few drugs have been approved by the Food and Drug Administration (FDA) for combating TB, which reflects the difficulties rampant in the discovery and clinical testing of new agents and the lack of pharmaceutical industry research in this area.³⁶ Hence, the discovery of fast-acting effective newer drugs to cure TB is imperative. Consequently, the novel poly functionalized piperidines (*viz.* enol form of piperidones) and pyridines synthesized in the present work

Chart 1. Synthesis of Tetrahydropyridines

Chart 2. Synthesis of Pentasubstituted Pyridines

* To whom correspondence should be addressed. e-mail: subbu.perum@gmail.com

have been screened as a part of our programme to unearth novel heterocyclic leads^{37–43)} for antimycobacterial activities and report the results in this paper.

Results and Discussion

Chemistry The four-component reaction of ethyl 3-oxo-4-(arylsulfanyl)butanoates (**1**), substituted aromatic aldehydes and ammonium acetate afforded the hitherto unreported ethyl 4-hydroxy-2,6-diaryl-5-(arylsulfanyl)-1,2,5,6-tetrahydro-3-pyridine-carboxylates (**2–4**) in moderate yields (Chart 1) following the methodology reported by Baliah and Noller for the synthesis of 2,6-diaryl piperidin-4-ones.⁴⁴⁾ The ethyl 3-oxo-4-(arylsulfanyl)butanoates were prepared by a literature method⁴⁵⁾ from the reaction of ethyl 4-chloroacetoacetate with substituted thiophenol in the presence of Et₃N in CH₂Cl₂.

A mixture of ethyl 3-oxo-4-(arylsulfanyl)butanoate, aromatic aldehyde and ammonium acetate in a molar ratio of 1:2:1 in ethanol was gently heated to boiling on a water bath until orange colour appeared and then the reaction mixture was kept aside for 1–2 d at ambient temperature. After completion of the reaction, the viscous liquid was dissolved in diethyl ether and the compound was isolated as hydrochloride, which was then neutralized with aqueous ammonia. The product, comprising three diastereomeric enols, **2–4** was extracted with ether and the enols separated by column chromatography.

The enols possess three stereocentres and exist in three diastereomeric forms, **2–4** differing in their configurations at 2, 5 and 6 positions. In case of entries 1–4, 9–12 and 17–20 where the aryl ring is *p*-substituted, the isomer **2** predominates over **3** and **4**. In **2**, H-5 and H-6 are *trans* to each other as evident from their *J* value of *ca.* 10 Hz and H-2 is *trans* to H-6. In the case of **b** and **c** (entries 2 and 3), the isomer **4** predominates over **2**, where the isomer **3** is not formed even in traces. In the case of entries 5–7, 13–15, 21 and 22 (**3e–g**, **3m–o**, **3u** and **3v**) where the aryl ring is *o*-substituted, the isomer **3** is obtained as the sole product and it is pertinent to note that H-5 and H-6 are in *cis* relationship. However, in the case of R' = *m*-NO₂ (entries 8, 6 and 23), the isomers **2** and **3** was obtained as an inseparable mixture, as they differ little in their *R_f* values. Repetition of this reaction also confirmed this observation. In compound **4**, H-5 and H-2 are respectively *trans* and *cis* to H-6. With the range of limited substituents on the aryl rings, it is not possible to discern any firm trend on the influence of the substituents on the product distribution. The structure of the diastereomeric enols was elucidated using NMR spectroscopic data, as illustrated for **2i** and **3i** as representative examples. The relative orientations of the aryl rings at 2 and 6 positions were unambiguously determined by X-ray crystallographic studies (*vide infra*).

The ¹H-NMR spectrum of **2i** shows a singlet at 4.97 ppm ascribable to H-2 on the basis of its singlet nature and its heteronuclear multiple bond correlations (HMBC) (Fig. 1) with (i) *ipso*- and *ortho*-carbons of the phenyl ring at C-2, (ii) C-3 at 96.7 ppm, (iii) C-4 at 155.1 ppm, (iv) the carboxy carbonyl at 169.0 ppm, and (v) C-6 at 56.2 ppm. The C,H-correlation of H-2 in conjunction with its chemical shift assigns the signal at 56.8 ppm to C-2. From C,H-COSY correlation spectra, the doublet at 3.72 ppm (*J* = 10.1 Hz) is assigned to H-6. The doublet at 3.82 ppm (*J* = 10.1 Hz) is due to H-5 as

Fig. 1. Selected HMBC Correlations of **2i** (*trans,trans*)

Fig. 2. ¹H and ¹³C Chemical Shifts of **2i** (*trans,trans*)

Fig. 3. ¹H and ¹³C Chemical Shifts of **3i** (*cis,cis*)

evident from its H,H-COSY correlation with H-6 and the signal at 53.9 ppm is assigned to C-5 from C,H-COSY correlation. Further, H-5 shows HMBC correlation with C-3 besides showing correlations with C-4 and C-6. The carboxy group affords a triplet at 0.93 ppm (*J* = 7.2 Hz) and a multiplet at 3.89–4.02 ppm. The NH and aromatic hydrogens appear as a singlet and multiplet at 1.74 and 6.79–7.23 ppm respectively.

The ¹H and ¹³C chemical shifts of **2i** and **3i** differ little. In the case of **3i**, H-6 appearing as a doublet at 4.51 ppm (*J* = 2.1 Hz) is deshielded relative to H-6 of **2i**. This may probably be taken as an evidence for the stereochemistry of **3i**, for which suitable crystals could not be grown and hence X-ray crystallographic studies could not be carried out. Presumably, the two phenyl rings in the case of **2i** shield H-6, while the two phenyl rings in **3i** are far away from H-6 and hence the latter is not shielded. A doublet of doublets at 3.56 ppm (*J* = 2.1, 1.2 Hz) is due to H-5 of **3i**, the *J* values respectively ascribable to vicinal coupling with H-6 and allylic coupling with OH. The *J* value of 2.1 Hz discloses their *cis* relationship as given in Fig. 3. The NH and OH hydrogens appear as broad singlets at 1.92 and 6.08 ppm respectively. The ¹H and ¹³C chemical shifts of **2i** and **3i** are depicted in Figs. 2 and 3 respectively. In the case of **4b**, H-2 appears as a singlet at 4.82 ppm and H-5, H-6 and CH₂ of carboxy group occur

Fig. 4. ORTEP Diagram of **2k** Fig. 5. ORTEP Diagram of **2t** Fig. 6. ORTEP Diagram of **4b** Fig. 7. ORTEP diagram of **4c**

as a multiplet at 3.78–3.95 ppm. The structures of **2** and **4** have been fully elucidated from X-ray crystallographic studies^{46–49}) (Figs. 4–7).

Subsequently, the ethyl 4-hydroxy-2,6-diaryl-5-(arylsulfanyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylates (**2–4**) were dehydrogenated with dichlorodicyanobenzoquinone (DDQ) in refluxing benzene to yield 4-hydroxy-2,6-diaryl-5-(aryl-

Fig. 8. ORTEP Diagram of **5a** Fig. 9. ORTEP Diagram of **5r**

sulfanyl)pyridine-carboxylates (**5**) in good yield (Chart 2). The major diastereomer in each case was subjected to dehydrogenation with DDQ. After completion of the reaction (TLC), the precipitated DDQ-H₂ was filtered off, the solvent removed and the residue crystallized from ethanol to afford the product **5**.

The structure of **5** is in accord with its NMR spectroscopic data. For instance, the ¹H-NMR spectrum for **5a** has a triplet and a quartet at 0.78 and 3.98 ppm ($J=7.2$ Hz) due to the ester function. The aromatic protons appear as a multiplet at 7.06–7.57 ppm, while the OH proton appears as a broad singlet at 6.57 ppm. X-ray crystallographic studies⁵⁰) (Figs. 8 and 9) also confirm the structure deduced from NMR spectroscopic data.

Biology Keto esters (**1**), tetrahydropyridines (**2–4**) and pyridines (**5**) were screened for their *in vitro* antimycobacterial activity against *Mycobacterium tuberculosis* H37Rv (MTB) by agar dilution method for the determination of minimum inhibitory concentration (MIC) in triplicates. The MIC is defined as the minimum concentration of compound required to completely inhibit the bacterial growth. The MIC values of **1–5** along with the standard drugs for comparison are furnished in Table 3.

The keto esters *viz.* ethyl 3-oxo-4-(arylsulfanyl)butanoates (**1**) afford MIC >91.66 μ M indicating that they are not significantly active against MTB. The tetrahydropyridine esters (**2–4**) showed good activity with MIC ranging from 6.50–57.94 μ M. All the tetrahydropyridine esters, except **2a**, showed good activity with higher activity than the first-line anti-TB drug pyrazinamide (MIC of 50.77 μ M). Three compounds, **2d**, **2s** and **2t**, with MIC of 6.81, 6.50 and 6.61 μ M

Table 1. Synthesis of Tetrahydropyridines

Entry	Compd.	R	R'	Yield (%)		
				2	3	4
1	a	H	H	45	7	—
2	b	H	<i>p</i> -Cl	6	—	54
3	c	H	<i>p</i> -F	5	—	50
4	d	H	<i>p</i> -CH ₃	42	6	—
5	e	H	<i>o</i> -Cl	—	52	—
6	f	H	<i>o</i> -Br	—	42	—
7	g	H	<i>o,p</i> -Cl ₂	—	55	—
8	h	H	<i>m</i> -NO ₂	—	53 ^{a)}	—
9	i	Cl	H	46	7	—
10	j	Cl	<i>p</i> -Cl	49	9	—
11	k	Cl	<i>p</i> -F	28	26	—
12	l	Cl	<i>p</i> -CH ₃	46	6	—
13	m	Cl	<i>o</i> -Cl	—	49	—
14	n	Cl	<i>o</i> -Br	—	40	—
15	o	Cl	<i>o,p</i> -Cl ₂	—	50	—
16	p	Cl	<i>m</i> -NO ₂	—	48 ^{a)}	—
17	q	CH ₃	H	46	8	—
18	r	CH ₃	<i>p</i> -Cl	50	7	—
19	s	CH ₃	<i>p</i> -F	28	26	—
20	t	CH ₃	<i>p</i> -CH ₃	50	8	—
21	u	CH ₃	<i>o</i> -Cl	—	50	—
22	v	CH ₃	<i>o,p</i> -Cl ₂	—	45	—
23	w	CH ₃	<i>m</i> -NO ₂	—	46 ^{a)}	—

a) In case of R'=*m*-NO₂ the products were obtained as an inseparable mixture of diastereomers.

Table 2. Synthesis of Pentasubstituted Pyridines

Entry	Compd. 5	R	R'	Yield (%)
1	a	H	H	73
2	b	H	<i>p</i> -Cl	84
3	c	H	<i>p</i> -F	75
4	d	H	<i>p</i> -CH ₃	72
5	e	H	<i>o</i> -Cl	77
6	f	H	<i>o</i> -Br	72
7	g	H	<i>o,p</i> -Cl ₂	82
8	h	H	<i>m</i> -NO ₂	75
9	i	Cl	H	76
10	j	Cl	<i>p</i> -Cl	87
11	k	Cl	<i>p</i> -F	78
12	l	Cl	<i>p</i> -CH ₃	72
13	m	Cl	<i>o</i> -Cl	80
14	n	Cl	<i>o</i> -Br	70
15	o	Cl	<i>o,p</i> -Cl ₂	79
16	p	CH ₃	H	70
17	q	CH ₃	<i>p</i> -Cl	79
18	r	CH ₃	<i>p</i> -F	72
19	s	CH ₃	<i>p</i> -CH ₃	70
20	t	CH ₃	<i>o</i> -Cl	74
21	u	CH ₃	<i>o,p</i> -Cl ₂	81
22	v	CH ₃	<i>m</i> -NO ₂	78

respectively are more potent than the standard drug ethambutol (MIC of 7.64 μ M). The pyridine esters **5** showed good activity with MICs ranging from 1.33—29.24 μ M. All the compounds of series **5** are more potent than pyrazinamide (MIC of 50.77 μ M). Ten compounds, **5c—g**, **5k**, **5p—r** and **5u**, with MIC ranging from 1.33—7.09 μ M are active than the drug ethambutol (MIC of 7.64 μ M).

In general, pyridines **5** display better activity than the tetrahydropyridine esters (Table 3). Among all the compounds screened, ethyl 2,6-di(2-bromophenyl)-4-hydroxy-5-

Table 3. Anti-mycobacterial Activities of Ketoesters **1**, Tetrahydropyridines **2—4** and Pyridines **5**

Compd.	(MTB) ^{a)}	Compd.	(MTB) ^{a)}
1a	>104.91	4b	24.98
1b	>91.66	4c	13.37
1c	>99.08	5a	29.24
2a	57.94	5b	25.18
2d	6.81	5c	6.75
2i	26.82	5d	6.87
2j	46.74	5e	6.30
2k	12.45	5f	1.33
2l	12.65	5h	12.08
2q	14.03	5i	27.06
2r	12.15	5j	23.55
2s	6.50	5k	6.29
2t	6.61	5l	12.75
3e	12.49	5m	23.55
3f	21.21	5n	10.08
3g	21.96	5o	10.42
3n	40.08	5p	7.09
3o	41.40	5q	6.13
3p	— ^{b)}	5r	3.27
3u	12.15	5s, t	— ^{b)}
3v	42.84	5u	5.40
3w	— ^{b)}	5v	23.52
Isoniazid			0.36
Rifampicin			0.12
Ethambutol			7.64
Pyrazinamide			50.77

a) Minimum inhibitory concentrations (μ M) against *Mycobacterium tuberculosis*.

b) Not tested.

(phenylsulfanyl)-3-pyridinecarboxylate (**5f**) showed the maximum activity with MIC of 1.33 μ M. Compared to isoniazid and rifampicin, all the compounds were less active. With regard to structure–activity point of view, most of the pyridines (**5**) were found to be more potent than the corresponding tetrahydropyridines (**2—4**). Presumably, the pyridines with enhanced planarity and hence less sterically demanding may have an advantage over tetrahydropyridine enols in penetrating the mycobacterial cell wall. It is found that the presence of (i) methyl group in the aryl ring of 5-arylsulfanyl moiety and (ii) electron-withdrawing groups like halogens in the aryl rings at 2,6-positions enhance the activity.

Conclusion

The present work describes a rapid access to a series of ethyl 4-hydroxy-2,6-diaryl-5-(arylsulfanyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylates by the four-component reaction of ethyl 3-oxo-4-(arylsulfanyl)butanoate, aromatic aldehyde and ammonium acetate. These tetrahydropyridine esters undergo facile dehydrogenation with DDQ to furnish the highly functionalised pyridines in excellent yields. These novel heterocycles showed good to excellent *in vitro* activity against *Mycobacterium tuberculosis* H37Rv. This protocol could be employed for generating a huge library of these biologically important compounds.

Experimental

General The melting points were taken using open capillary tubes and are uncorrected. ¹H, ¹³C and 2D NMR spectra were recorded on a Bruker (Avance) 300 MHz instrument in CDCl₃ using tetramethylsilane (TMS) as internal standard. Chemical shifts are given in parts per million (δ -scale) and the coupling constants are given in Hertz. IR spectra were recorded on a JASCO FT IR instrument (KBr pellet in case of solids and CHCl₃ in case of

viscous liquids). Elemental analyses were performed on a Perkin Elmer 2400 Series II Elemental CHNS analyser. High resolution mass spectra (HR-MS) were recorded in Thermo-Scientific mass spectrometer using ESI probe. Column chromatography was performed on silica gel (230–400 mesh) using petroleum ether–ethyl acetate (8:2 v/v) as eluent. Crystals suitable for X-ray crystallographic studies were obtained by recrystallisation from petroleum ether–ethyl acetate mixture.

Synthesis of Ethyl 4-Hydroxy-2,6-diaryl-5-(arylsulfanyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylates (2–4). **General Procedure** To a solution of ammonium acetate (0.1 g, 1.3 mmol) in ethyl alcohol (30 ml), a mixture of ethyl 3-oxo-4-(phenylsulfanyl)butanoate (0.3 g, 1.3 mmol) and freshly distilled aromatic aldehyde (2.6 mmol) was added and warmed on a water bath until the solution became orange and the reaction mixture set aside at room temperature for 1–2 d. To this reaction mixture, diethyl ether (100 ml) was added and the solid mass obtained was filtered off. To the clear filtrate, concentrated hydrochloric acid (2 ml) was added with stirring. The solid piperidine hydrochlorides obtained were washed with diethyl ether (50 ml), suspended in acetone, neutralized with ammonia, diluted with ice-water, extracted with diethyl ether, and dried over anhydrous sodium sulphate. After removing the solvent, the product mixture was separated in a pure state by column chromatography over silica gel using petroleum ether–ethyl acetate mixture as eluent. The products were further purified by recrystallisation using petroleum ether–ethyl acetate (8:2 v/v).

Ethyl 4-Hydroxy-2,6-diphenyl-5-(phenylsulfanyl)-1,2,5,6-tetrahydro-3-pyridine-carboxylate (2a): Isolated as white solid; (0.245 g, 45%); mp 116–117 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.92 (t, $J=7.2$ Hz, 3H, CH_3), 3.79 (d, $J=10.0$ Hz, 1H, H-6), 3.84 (d, $J=10.0$ Hz, 1H, H-5), 3.88–4.12 (m, 2H, CH_2), 4.97 (s, 1H, H-2), 6.83–7.28 (m, 15H, aromatic). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 14.5, 53.9, 56.2, 57.0, 59.5, 96.3, 126.7, 127.8, 128.2, 128.4, 128.5, 128.9, 129.3, 129.6, 131.1, 135.4, 142.1, 144.6, 155.7, 169.0. IR (KBr) ν_{max} : 746, 1228, 1261, 1525, 1604, 1664, 2981, 3309, 3446 cm^{-1} ; *Anal.* Calcd for $\text{C}_{26}\text{H}_{25}\text{NO}_3\text{S}$: C, 72.36; H, 5.84; N, 3.25; Found: C, 72.30; H, 5.88; N, 3.29.

Ethyl 4-Hydroxy-2,6-diphenyl-5-(phenylsulfanyl)-1,2,5,6-tetrahydro-3-pyridine-carboxylate (3a): Isolated as colorless solid; (0.036 g, 7%); mp 112–114 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.83 (t, $J=6.9$ Hz, 3H, CH_3), 1.72 (brs, 1H, NH), 3.62 (s, 1H, H-5), 3.85–4.12 (m, 2H, CH_2), 4.51 (s, 1H, H-6), 4.97 (s, 1H, H-2), 6.07 (brs, 1H, OH), 6.90–7.38 (m, 15H, aromatic). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 14.2, 58.5, 59.4, 59.6, 60.0, 97.2, 127.3, 127.8, 128.0, 128.2, 128.4, 128.5, 129.3, 133.2, 136.2, 140.1, 146.3, 157.3, 169.3. IR (KBr) ν_{max} : 745, 1226, 1260, 1526, 1602, 1667, 2984, 3313, 3442 cm^{-1} ; *Anal.* Calcd for $\text{C}_{26}\text{H}_{25}\text{NO}_3\text{S}$: C, 72.36; H, 5.84; N, 3.25. Found: C, 72.32; H, 5.80; N, 3.31.

Ethyl 2,6-Di(4-chlorophenyl)-4-hydroxy-5-(phenylsulfanyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (2b): Isolated as colorless crystals; (0.038 g, 6%); mp 110–112 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.94 (t, $J=7.2$ Hz, 3H, CH_3), 3.70 (d, $J=10.0$ Hz, 1H, H-6), 3.76 (d, $J=10.0$ Hz, 1H, H-5), 3.89–4.02 (m, 2H, CH_2), 4.91 (s, 1H, H-2), 6.74–7.45 (m, 13H, aromatic). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 14.5, 53.5, 55.6, 56.3, 59.6, 96.0, 128.4, 129.1, 129.2, 129.6, 129.7, 129.8, 130.6, 132.5, 134.2, 135.6, 140.3, 143.1, 155.5, 168.8. IR (KBr) ν_{max} : 738, 1230, 1261, 1529, 1604, 1664, 2987, 3313, 3453 cm^{-1} ; *Anal.* Calcd for $\text{C}_{26}\text{H}_{23}\text{Cl}_2\text{NO}_3\text{S}$: C, 62.40; H, 4.63; N, 2.80. Found: C, 62.46; H, 4.57; N, 2.84.

Ethyl 2,6-Di(4-chlorophenyl)-4-hydroxy-5-(phenylsulfanyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (4b): Isolated as colorless crystals; (0.340 g, 54%); mp 158–159 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.82 (t, $J=7.2$ Hz, 3H, CH_3), 3.78–3.95 (m, 4H, H-5, H-6, CH_2), 4.82 (s, 1H, H-2), 7.11–7.23 (m, 13H, aromatic). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 14.2, 55.8, 59.4, 59.5, 62.1, 98.3, 128.3, 128.4, 128.9, 129.5, 129.6, 129.8, 132.7, 132.8, 132.9, 134.2, 140.1, 145.3, 155.5, 168.9. IR (KBr) ν_{max} : 740, 1232, 1260, 1527, 1601, 1665, 2985, 3310, 3451 cm^{-1} ; *Anal.* Calcd for $\text{C}_{26}\text{H}_{23}\text{Cl}_2\text{NO}_3\text{S}$: C, 62.40; H, 4.63; N, 2.80. Found: C, 62.36; H, 4.69; N, 2.86.

Ethyl 2,6-Di(4-fluorophenyl)-4-hydroxy-5-(phenylsulfanyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (2c): Isolated as colorless crystals; (0.030 g, 5%); mp 109–110 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.91 (t, $J=7.2$ Hz, 3H, CH_3), 3.73 (d, $J=9.5$ Hz, 1H, H-6), 3.82 (d, $J=9.5$ Hz, 1H, H-5), 3.87–4.09 (m, 2H, CH_2), 4.95 (s, 1H, H-2), 6.77–7.56 (m, 13H, aromatic). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 14.6, 53.6, 55.4, 56.7, 59.7, 96.0, 115.0, 115.2, 115.5, 115.8, 128.3, 129.5, 129.7, 129.9, 130.2, 132.1, 133.1, 136.1, 143.7, 160.3, 161.2, 163.5, 165.2, 155.5, 168.3. IR (KBr) ν_{max} : 737, 1231, 1263, 1530, 1604, 1665, 2989, 3314, 3451 cm^{-1} ; *Anal.* Calcd for $\text{C}_{26}\text{H}_{23}\text{F}_2\text{NO}_3\text{S}$: C, 66.79; H, 4.96; N, 3.00. Found: C, 66.85; H, 4.91; N, 3.07.

Ethyl 2,6-Di(4-fluorophenyl)-4-hydroxy-5-(phenylsulfanyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (4c): Isolated as colorless crystals; (0.295 g,

50%); mp 158–160 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.81 (t, $J=7.2$ Hz, 3H, CH_3), 3.77–3.95 (m, 3H, H-5, H-6, CH_2), 4.83 (s, 1H, H-2), 6.89–7.22 (m, 13H, aromatic). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 14.5, 56.0, 59.3, 59.4, 62.0, 98.7, 114.9, 115.1, 115.4, 115.7, 128.2, 129.4, 129.6, 129.7, 130.0, 132.9, 133.0, 137.5, 142.5, 160.6, 161.2, 163.8, 164.5, 155.5, 169.0. IR (KBr) ν_{max} : 749, 1232, 1262, 1528, 1602, 1668, 2987, 3309, 3455 cm^{-1} ; *Anal.* Calcd for $\text{C}_{26}\text{H}_{23}\text{F}_2\text{NO}_3\text{S}$: C, 66.79; H, 4.96; N, 3.00. Found: C, 66.75; H, 4.92; N, 3.05.

Ethyl 4-Hydroxy-2,6-di(4-methylphenyl)-5-(phenylsulfanyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (2d): Isolated as colorless crystals; (0.242 g, 42%); mp 128–129 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.94 (t, $J=7.2$ Hz, 3H, CH_3), 2.27 (s, 1H, CH_3), 2.32 (s, 1H, CH_3), 3.76 (d, $J=10.2$ Hz, 1H, H-6), 3.82 (d, $J=10.2$ Hz, 1H, H-5), 3.87–4.03 (m, 2H, CH_2), 4.93 (s, 1H, H-2), 6.70–7.43 (m, 13H, aromatic). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 14.6, 54.0, 55.8, 56.7, 59.5, 96.6, 127.7, 128.4, 128.9, 129.2, 129.5, 129.6, 131.2, 135.4, 136.1, 138.1, 139.3, 141.7, 155.7, 169.1. IR (KBr) ν_{max} : 738, 1229, 1260, 1520, 1601, 1667, 2988, 3306, 3449 cm^{-1} ; *Anal.* Calcd for $\text{C}_{28}\text{H}_{29}\text{NO}_3$: C, 73.17; H, 6.36; N, 3.05. Found: C, 73.12; H, 6.30; N, 3.00.

Ethyl 4-Hydroxy-2,6-di(4-methylphenyl)-5-(phenylsulfanyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (3d): Isolated as colorless crystals; (0.035 g, 6%); mp 111–112 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.85 (t, $J=6.9$ Hz, 3H, CH_3), 1.89 (brs, 1H, NH), 2.29 (s, 1H, CH_3), 2.34 (s, 1H, CH_3), 3.60 (d, $J=1.8$ Hz, 1H, H-5), 3.84–4.10 (m, 2H, CH_2), 4.44 (d, $J=1.8$ Hz, 1H, H-6), 4.93 (s, 1H, H-2), 6.00 (brs, 1H, OH), 6.89–7.47 (m, 13H, aromatic). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 13.8, 21.1, 21.2, 58.2, 58.9, 58.9, 59.1, 96.4, 127.0, 127.2, 127.4, 127.9, 128.5, 128.7, 128.8, 132.8, 136.3, 136.7, 136.9, 143.0, 156.7, 169.0. IR (KBr) ν_{max} : 740, 1225, 1262, 1526, 1607, 1662, 2984, 3312, 3445 cm^{-1} ; *Anal.* Calcd for $\text{C}_{28}\text{H}_{29}\text{NO}_3\text{S}$: C, 73.17; H, 6.36; N, 3.05. Found: C, 73.24; H, 6.31; N, 3.11.

Ethyl 2,6-Di(2-chlorophenyl)-4-hydroxy-5-(phenylsulfanyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (3e): Isolated as colorless crystals; (0.325 g, 52%); mp 141–142 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.84 (t, $J=7.2$ Hz, 3H, CH_3), 1.94 (brs, 1H, NH), 3.77–3.97 (m, 2H, CH_2), 3.98–4.05 (m, 1H, H-5), 4.81 (s, 1H, H-6), 5.55 (s, 1H, H-2), 6.18 (brs, 1H, OH), 6.93–7.55 (m, 13H, aromatic). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 13.6, 54.1, 55.0, 56.3, 59.0, 95.3, 126.7, 127.1, 127.3, 127.9, 128.6, 128.7, 128.8, 128.9, 129.9, 132.0, 132.4, 133.7, 135.6, 136.9, 143.4, 157.1, 168.5. IR (KBr) ν_{max} : 740, 1221, 1265, 1523, 1612, 1669, 2989, 3319, 3447 cm^{-1} ; *Anal.* Calcd for $\text{C}_{26}\text{H}_{23}\text{Cl}_2\text{NO}_3\text{S}$: C, 62.40; H, 4.63; N, 2.80. Found: C, 62.47; H, 4.58; N, 2.86.

Ethyl 2,6-Di(2-bromophenyl)-4-hydroxy-5-(phenylsulfanyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (3f): Isolated as colorless crystals; (0.310 g, 42%); mp 135–136 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.90 (t, $J=7.2$ Hz, 3H, CH_3), 1.97 (brs, 1H, NH), 3.88–4.07 (m, 2H, CH_2), 4.20 (s, 1H, H-5), 4.77 (s, 1H, H-6), 5.48 (s, 1H, H-2), 6.98–7.58 (m, 13H, aromatic), 12.3 (s, 1H, OH). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 13.2, 52.8, 56.4, 58.6, 60.2, 100.6, 109.0, 122.7, 126.8, 126.9, 127.7, 128.3, 128.8, 130.1, 131.8, 133.3, 133.9, 134.3, 134.8, 134.9, 135.2, 142.3, 157.1, 170.5. IR (KBr) ν_{max} : 741, 1224, 1262, 1520, 1614, 1667, 2990, 3317, 3445 cm^{-1} ; *Anal.* Calcd for $\text{C}_{26}\text{H}_{23}\text{Br}_2\text{NO}_3\text{S}$: C, 52.99; H, 3.93; N, 2.38. Found: C, 53.05; H, 4.01; N, 2.30.

Ethyl 2,6-Di(2,4-dichlorophenyl)-4-hydroxy-5-(phenylsulfanyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (3g): Isolated as pale yellow solid; (0.395 g, 55%); mp 150–151 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.96 (t, $J=7.2$ Hz, 3H, CH_3), 1.88 (brs, 1H, NH), 3.92–4.09 (m, 2H, CH_2), 4.15 (s, 1H, H-5), 4.74 (s, 1H, H-6), 5.44 (s, 1H, H-2), 7.02–7.31 (m, 9H, aromatic), 7.38 (d, $J=1.8$ Hz, 1H, aromatic), 7.47 (d, $J=8.4$ Hz, 1H, aromatic), 12.3 (s, 1H, OH). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 13.5, 52.8, 52.9, 56.1, 60.7, 100.6, 126.7, 127.3, 127.6, 128.4, 128.6, 129.9, 130.6, 132.1, 132.9, 133.3, 133.9, 134.3, 134.8, 134.9, 140.3, 170.4, 170.6. IR (KBr) ν_{max} : 739, 1225, 1266, 1522, 1618, 1668, 2988, 3317, 3441 cm^{-1} ; *Anal.* Calcd for $\text{C}_{26}\text{H}_{21}\text{Cl}_4\text{NO}_3\text{S}$: C, 54.85; H, 3.72; N, 2.46. Found: C, 54.78; H, 3.80; N, 2.39.

Ethyl 4-Hydroxy-2,6-di(3-nitrophenyl)-5-(phenylsulfanyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (2h and 3h) (Appears as Mixture in a Ratio 1:0.62): Isolated as viscous liquid; (0.350 g, 53%); $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.95–1.05 (m, CH_3), 3.94–4.16 (m, CH_2), 4.26–4.37 (m, H-5), 4.52–5.13 (m, H-6, H-2), 7.06–8.20 (m, aromatic), 12.6 (s, OH), 12.9 (s, OH). HR-MS (ESI) m/z Calcd for $\text{C}_{26}\text{H}_{23}\text{N}_3\text{O}_7\text{S}$: 521.1257; Found: 520.2402 (M–1).

Ethyl 5-[(4-Chlorophenyl)sulfanyl]-4-hydroxy-2,6-diphenyl-1,2,5,6-tetrahydro-3-pyridinecarboxylate (2i): Isolated as colorless crystals; (0.236 g, 46%); mp 121–122 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.93 (t, $J=7.2$ Hz, 3H, CH_3), 1.74 (s, 1H, NH), 3.72 (d, $J=10.1$ Hz, 1H, H-6), 3.82 (d, $J=10.1$ Hz,

1H, H-5), 3.89–4.02 (m, 2H, CH₂), 4.97 (s, 1H, H-2), 6.79–7.23 (m, 14H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 14.5, 53.9, 56.2, 56.8, 59.6, 96.7, 127.0, 127.7, 128.2, 128.4, 128.6, 129.0, 129.2, 129.6, 135.8, 137.1, 141.8, 144.4, 155.1, 169.0. IR (KBr) ν_{max}: 740, 1230, 1261, 1529, 1604, 1664, 2987, 3313, 3453 cm⁻¹; *Anal.* Calcd for C₂₆H₂₄ClNO₃S: C, 67.01; H, 5.19; N, 3.01. Found: C, 67.08; H, 5.25; N, 3.06.

Ethyl 5-[(4-Chlorophenyl)sulfanyl]-4-hydroxy-2,6-diphenyl-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**3i**): Isolated as colorless crystals; (0.036 g, 7%); mp 115–117 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.83 (t, *J*=7.2 Hz, 3H, CH₃), 1.92 (brs, 1H, NH), 3.56 (dd, *J*=2.1, 1.2 Hz, 1H, H-5), 3.76–3.98 (m, 2H, CH₂), 4.51 (d, *J*=2.1 Hz, 1H, H-6), 4.96 (s, 1H, H-2), 6.08 (brs, 1H, OH), 6.79–7.26 (m, 14H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 14.5, 58.8, 59.5, 59.6, 59.9, 97.1, 127.3, 127.8, 128.0, 128.4, 128.5, 128.6, 129.4, 134.2, 134.6, 140.0, 146.2, 156.5, 169.3. IR (KBr) ν_{max}: 743, 1235, 1262, 1526, 1601, 1668, 2992, 3318, 3446 cm⁻¹; *Anal.* Calcd for C₂₆H₂₄ClNO₃S: C, 67.01; H, 5.19; N, 3.01. Found: C, 66.97; H, 5.13; N, 3.08.

Ethyl 2,6-Di(4-chlorophenyl)-5-[(4-chlorophenyl)sulfanyl]-4-hydroxy-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**2j**): Isolated as colorless crystals; (0.290 g, 49%); mp 119–120 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.96 (t, *J*=7.2 Hz, 3H, CH₃), 3.63 (d, *J*=9.9 Hz, 1H, H-6), 3.74 (d, *J*=9.9 Hz, 1H, H-5), 3.91–4.03 (m, 2H, CH₂), 4.91 (s, 1H, H-2), 6.73–7.37 (m, 12H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 14.2, 53.5, 55.7, 56.1, 59.6, 96.5, 128.4, 128.9, 129.0, 129.2, 129.7, 129.9, 132.7, 134.4, 136.1, 137.0, 140.1, 143.0, 155.0, 168.7. IR (KBr) ν_{max}: 736, 1236, 1260, 1525, 1602, 1665, 2984, 3310, 3450 cm⁻¹; *Anal.* Calcd for C₂₆H₂₂Cl₃NO₃S: C, 58.38; H, 4.15; N, 2.62. Found: C, 58.31; H, 4.20; N, 2.56.

Ethyl 2,6-Di(4-chlorophenyl)-5-[(4-chlorophenyl)sulfanyl]-4-hydroxy-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**3j**): Isolated as colorless crystals; (0.053 g, 9%); mp 109–110 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.89 (t, *J*=7.2 Hz, 3H, CH₃), 1.92 (brs, 1H, NH), 3.54 (s, 1H, H-5), 3.80–3.99 (m, 2H, CH₂), 4.46 (d, *J*=1.8 Hz, 1H, H-6), 4.93 (s, 1H, H-2), 6.11 (brs, 1H, OH), 6.87–7.28 (m, 12H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 14.3, 58.4, 59.1, 59.2, 59.6, 96.6, 128.6, 128.7, 129.1, 129.5, 129.8, 133.0, 133.9, 134.1, 134.6, 138.4, 144.7, 156.5, 169.0. IR (KBr) ν_{max}: 739, 1231, 1262, 1527, 1602, 1660, 2989, 3315, 3451 cm⁻¹; *Anal.* Calcd for C₂₆H₂₂Cl₃NO₃S: C, 58.38; H, 4.15; N, 2.62. Found: C, 58.45; H, 4.21; N, 2.66.

Ethyl 5-[(4-Chlorophenyl)sulfanyl]-2,6-di(4-fluorophenyl)-4-hydroxy-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**2k**): Isolated as colorless crystals; (0.155 g, 28%); mp 129–130 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.95 (t, *J*=7.2 Hz, 3H, CH₃), 3.66 (d, *J*=10.1 Hz, 1H, H-6), 3.74 (d, *J*=10.1 Hz, 1H, H-5), 3.91–4.02 (m, 2H, CH₂), 4.93 (s, 1H, H-2), 6.73–7.30 (m, 12H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 14.5, 53.9, 55.5, 56.1, 59.6, 96.8, 114.9, 115.1, 115.8, 116.0, 129.0, 129.1, 129.5, 129.8, 129.9, 130.0, 136.0, 137.1, 137.5, 137.6, 140.3, 140.4, 160.3, 161.2, 163.5, 164.5, 155.0, 168.8. IR (KBr) ν_{max}: 735, 1230, 1262, 1521, 1606, 1664, 2988, 3314, 3445 cm⁻¹; *Anal.* Calcd for C₂₆H₂₂ClF₂NO₃S: C, 62.21; H, 4.42; N, 2.79. Found: C, 62.17; H, 4.37; N, 2.85.

Ethyl 5-[(4-Chlorophenyl)sulfanyl]-2,6-di(4-fluorophenyl)-4-hydroxy-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**3k**): Isolated as colorless crystals; (0.144 g, 26%); mp 112–113 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.88 (t, *J*=7.2 Hz, 3H, CH₃), 1.79 (brs, 1H, NH), 3.52 (d, 1H, *J*=1.8 Hz, H-5), 3.81–4.00 (m, 1H, CH₂), 4.47 (d, 1H, *J*=1.8 Hz, H-6), 4.94 (s, 1H, H-2), 6.85–7.30 (m, 12H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 14.3, 58.7, 59.0, 59.2, 59.5, 96.6, 115.1, 115.3, 115.4, 115.6, 129.3, 129.4, 129.5, 129.8, 130.0, 134.3, 134.4, 134.5, 135.7, 135.8, 141.9, 142.0, 160.7, 161.0, 163.9, 164.2, 156.5, 169.1. IR (KBr) ν_{max}: 738, 1236, 1260, 1524, 1601, 1662, 2985, 3310, 3447 cm⁻¹; *Anal.* Calcd for C₂₆H₂₂ClF₂NO₃S: C, 62.21; H, 4.42; N, 2.79. Found: C, 62.27; H, 4.48; N, 2.72.

Ethyl 5-[(4-Chlorophenyl)sulfanyl]-4-hydroxy-2,6-di(4-methylphenyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**2l**): Isolated as colorless crystals; (0.250 g, 46%); mp 131–132 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.96 (t, *J*=6.9 Hz, 3H, CH₃), 2.29 (s, 1H, CH₃), 2.32 (s, 1H, CH₃), 3.67 (d, *J*=9.9 Hz, 1H, H-6), 3.79 (d, *J*=9.9 Hz, 1H, H-5), 3.85–4.03 (m, 2H, CH₂), 4.93 (s, 1H, H-2), 6.66–7.43 (m, 12H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 14.3, 21.5, 21.6, 53.9, 55.8, 56.4, 59.5, 97.1, 127.6, 128.3, 128.9, 129.5, 29.7, 135.7, 136.3, 137.0, 138.3, 139.0, 141.5, 155.1, 169.1. IR (KBr) ν_{max}: 739, 1237, 1265, 1528, 1602, 1668, 2993, 3308, 3450 cm⁻¹; *Anal.* Calcd for C₂₈H₂₈ClNO₃S: C, 68.07; H, 5.71; N, 2.84. Found: C, 68.13; H, 5.76; N, 2.79.

Ethyl 5-[(4-Chlorophenyl)sulfanyl]-4-hydroxy-2,6-di(4-methylphenyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**3l**): Isolated as colorless crystals; (0.033 g, 6%); mp 120–122 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.94 (t, *J*=7.2 Hz, 3H, CH₃), 2.29 (s, 1H, CH₃), 2.30 (s, 1H, CH₃), 3.67 (s, 1H, H-5), 3.82–4.03 (m, 1H, CH₂), 4.57 (d, 1H, *J*=1.8 Hz, H-6), 4.97 (s, 1H, H-2),

6.67–7.41 (m, 12H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 14.6, 21.5, 21.6, 58.4, 59.4, 59.6, 60.2, 96.5, 127.5, 128.4, 129.0, 129.3, 129.4, 129.7, 135.9, 136.5, 137.3, 138.6, 141.0, 142.5, 156.5, 169.1. IR (KBr) ν_{max}: 742, 1234, 1269, 1521, 1603, 1664, 2990, 3305, 3442 cm⁻¹; *Anal.* Calcd for C₂₈H₂₈ClNO₃S: C, 68.07; H, 5.71; N, 2.84. Found: C, 68.12; H, 5.66; N, 2.88.

Ethyl 2,6-Di(2-chlorophenyl)-5-[(4-chlorophenyl)sulfanyl]-4-hydroxy-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**3m**): Isolated as colorless crystals; (0.290 g, 49%); mp 138–139 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.84 (t, *J*=7.2 Hz, 3H, CH₃), 1.94 (brs, 1H, NH), 3.78–3.96 (m, 2H, CH₂), 3.97–4.03 (m, 1H, H-5), 4.81 (d, *J*=1.5 Hz, 1H, H-6), 5.55 (s, 1H, H-2), 6.22 (brs, 1H, OH), 6.87 (d, *J*=8.4 Hz, 2H, aromatic), 7.07 (d, *J*=8.4 Hz, 2H, aromatic), 7.15–7.54 (m, 8H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 13.6, 54.3, 55.0, 56.3, 59.1, 95.7, 126.7, 127.1, 127.9, 128.7, 128.8, 129.8, 129.8, 132.4, 133.4, 133.5, 133.7, 133.9, 136.8, 143.2, 156.4, 168.5. IR (KBr) ν_{max}: 740, 1225, 1261, 1523, 1614, 1661, 2986, 3319, 3445 cm⁻¹; *Anal.* Calcd for C₂₆H₂₂Cl₃NO₃S: C, 58.38; H, 4.15; N, 2.62. Found: C, 58.32; H, 4.22; N, 2.57.

Ethyl 2,6-Di(2-bromophenyl)-5-[(4-chlorophenyl)sulfanyl]-4-hydroxy-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**3n**): Isolated as colorless solid; (0.274 g, 40%); mp 121–122 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.90 (t, *J*=7.2 Hz, 3H, CH₃), 1.97 (brs, 1H, NH), 3.91–4.05 (m, 2H, CH₂), 4.14 (s, 1H, H-5), 4.77 (s, 1H, H-6), 5.47 (s, 1H, H-2), 6.91–7.57 (m, 12H, aromatic), 12.3 (s, 1H, OH). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 13.5, 53.4, 56.6, 58.8, 60.6, 101.1, 123.0, 127.1, 127.9, 128.7, 129.2, 129.3, 130.2, 130.4, 132.3, 133.4, 133.6, 134.0, 134.8, 134.9, 137.8, 140.3, 157.1, 170.7. IR (KBr) ν_{max}: 741, 1229, 1260, 1526, 1619, 1665, 2985, 3316, 3442 cm⁻¹; *Anal.* Calcd for C₂₆H₂₂Br₂ClNO₃S: C, 50.06; H, 3.55; N, 2.25. Found: C, 50.15; H, 3.49; N, 2.20.

Ethyl 5-[(4-Chlorophenyl)sulfanyl]-2,6-di(2,4-dichlorophenyl)-4-hydroxy-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**3o**): Isolated as pale yellow solid; (0.332 g, 50%); mp 156–157 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.96 (t, *J*=7.2 Hz, 3H, CH₃), 1.87 (brs, 1H, NH), 3.92–4.03 (m, 2H, CH₂), 4.06 (s, 1H, H-5), 4.75 (s, 1H, H-6), 5.44 (s, 1H, H-2), 6.96–7.38 (m, 9H, aromatic), 7.47 (d, *J*=8.4 Hz, 1H), 12.3 (s, 1H, OH). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 13.5, 53.2, 56.2, 59.0, 60.8, 100.7, 126.8, 127.7, 128.6, 128.7, 128.8, 130.0, 130.6, 133.0, 133.4, 133.5, 133.6, 133.7, 134.1, 134.3, 134.9, 140.2, 170.3, 170.5. IR (KBr) ν_{max}: 739, 1228, 1260, 1527, 1615, 1660, 2984, 3318, 3447 cm⁻¹; *Anal.* Calcd for C₂₆H₂₀Cl₅NO₃S: C, 51.72; H, 3.34; N, 2.32. Found: C, 51.80; H, 3.25; N, 2.26.

Ethyl 5-[(4-Chlorophenyl)sulfanyl]-4-hydroxy-2,6-di(3-nitrophenyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**2p** and **3p**): (Appears as Mixture in a Ratio 1 : 0.88): Isolated as viscous liquid; (0.293 g, 48%); ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.84–1.05 (m, CH₃), 3.82–4.16 (m, CH₂), 4.56–4.65 (m, H-5), 4.80–5.15 (m, H-6, H-2), 7.08–8.27 (m, aromatic), 12.6 (s, OH), 12.9 (s, OH). HR-MS (ESI) *m/z*: Calcd for C₂₆H₂₂³⁵ClN₃O₇S: 555.0867; Found, 554.3712 (M–1).

Ethyl 4-Hydroxy-5-[(4-methylphenyl)sulfanyl]-2,6-diphenyl-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**2q**): Isolated as colorless crystals; (0.244 g, 46%); mp 110–111 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.92 (t, *J*=7.2 Hz, 3H, CH₃), 2.41 (s, 1H, CH₃), 3.78 (s, 2H, H-5, H-6), 3.87–4.01 (m, 2H, CH₂), 4.95 (s, 1H, H-2), 6.78–7.29 (m, 14H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 14.5, 21.7, 53.8, 56.0, 57.0, 59.4, 96.4, 126.7, 127.1, 127.8, 128.1, 128.4, 128.5, 128.9, 130.4, 136.0, 139.6, 142.2, 144.6, 155.8, 169.0. IR (KBr) ν_{max}: 735, 1234, 1261, 1525, 1605, 1662, 2990, 3311, 3442 cm⁻¹; *Anal.* Calcd for C₂₇H₂₇NO₃S: C, 72.78; H, 6.11; N, 3.14. Found: C, 72.84; H, 6.17; N, 3.21.

Ethyl 4-Hydroxy-5-[(4-methylphenyl)sulfanyl]-2,6-diphenyl-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**3q**): Isolated as colorless crystals; (0.042 g, 8%); mp 107–108 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.74 (t, *J*=7.2 Hz, 3H, CH₃), 1.79 (brs, 1H, NH), 3.45 (s, 1H, H-5), 3.69–4.02 (m, 2H, CH₂), 4.40 (d, *J*=1.5 Hz, 1H, H-6), 4.87 (s, 1H, H-2), 6.00 (brs, 1H, OH), 6.72–7.41 (m, 14H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 13.7, 58.3, 58.9, 59.1, 59.5, 96.0, 126.8, 127.3, 127.9, 128.0, 128.1, 128.3, 129.6, 131.9, 135.5, 137.9, 139.8, 145.9, 157.1, 168.9. IR (KBr) ν_{max}: 738, 1231, 1265, 1529, 1601, 1659, 2993, 3315, 3440 cm⁻¹; *Anal.* Calcd for C₂₇H₂₇NO₃S: C, 72.78; H, 6.11; N, 3.14. Found: C, 72.82; H, 6.07; N, 3.20.

Ethyl 2,6-Di(4-chlorophenyl)-4-hydroxy-5-[(4-methylphenyl)sulfanyl]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**2r**): Isolated as colorless crystals; (0.306 g, 50%); mp 148–149 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.95 (t, *J*=7.2 Hz, 3H, CH₃), 2.43 (s, 1H, CH₃), 3.68 (s, 2H, H-5, H-6), 3.89–4.02 (m, 2H, CH₂), 4.90 (s, 1H, H-2), 6.71–7.33 (m, 12H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 14.5, 21.7, 53.4, 55.4, 56.2, 59.6, 96.2, 126.7, 128.3, 129.1, 129.2, 129.8, 130.5, 132.4, 134.2, 136.0, 139.9, 140.5, 143.2, 155.7,

168.8. IR (KBr) $\nu_{\max}$: 739, 1230, 1267, 1525, 1601, 1660, 2987, 3308, 3445 cm^{-1} ; *Anal.* Calcd for $\text{C}_{27}\text{H}_{25}\text{Cl}_2\text{NO}_3\text{S}$: C, 63.03; H, 4.90; N, 2.72. Found: C, 63.09; H, 4.84; N, 2.67.

Ethyl 2,6-Di(4-chlorophenyl)-4-hydroxy-5-[(4-methylphenyl)sulfanyl]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**3r**): Isolated as colorless crystals; (0.043 g, 7%); mp 144–146 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.89 (t, $J=7.2$ Hz, 3H, CH_3), 1.79 (brs, 1H, NH), 2.29 (s, 1H, CH_3), 3.53 (dd, 1H, $J=2.1, 1.2$ Hz, H-5), 3.84–3.95 (m, 2H, CH_2), 4.45 (d, $J=2.1$ Hz, 1H, H-6), 4.92 (s, 1H, H-2), 6.12 (brs, 1H, OH), 6.85–7.33 (m, 12H, aromatic). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 14.3, 21.5, 58.2, 59.0, 59.2, 59.5, 95.9, 128.6, 129.1, 129.8, 130.3, 131.9, 132.9, 133.6, 133.7, 138.6, 138.7, 140.4, 144.9, 157.3, 169.1. IR (KBr) $\nu_{\max}$: 738, 1235, 1262, 1524, 1606, 1665, 2991, 3312, 3441 cm^{-1} ; *Anal.* Calcd for $\text{C}_{27}\text{H}_{25}\text{Cl}_2\text{NO}_3\text{S}$: C, 63.03; H, 4.90; N, 2.72. Found: C, 63.10; H, 4.95; N, 2.76.

Ethyl 2,6-Di(4-fluorophenyl)-4-hydroxy-5-[(4-methylphenyl)sulfanyl]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**2s**): Isolated as colorless crystals; (0.160 g, 28%); mp 112–113 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.94 (t, $J=7.2$ Hz, 3H, CH_3), 2.43 (s, 1H, CH_3), 3.70 (s, 2H, H-5, H-6), 3.86–4.03 (m, 2H, CH_2), 4.92 (s, 1H, H-2), 6.68–7.19 (m, 12H, aromatic). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 14.5, 21.7, 53.7, 55.3, 56.2, 59.5, 96.4, 114.7, 115.0, 115.7, 116.0, 126.8, 129.2, 129.3, 130.0, 130.1, 130.4, 136.0, 137.8, 137.9, 139.8, 140.4, 140.5, 160.2, 161.1, 163.4, 164.4, 155.6, 168.8. IR (KBr) $\nu_{\max}$: 738, 1230, 1264, 1530, 1609, 1662, 2997, 3306, 3440 cm^{-1} ; *Anal.* Calcd for $\text{C}_{27}\text{H}_{25}\text{F}_2\text{NO}_3\text{S}$: C, 67.34; H, 5.23; N, 2.91. Found: C, 67.30; H, 5.29; N, 2.85.

Ethyl 2,6-Di(4-fluorophenyl)-4-hydroxy-5-[(4-methylphenyl)sulfanyl]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**3s**): Isolated as colorless crystals; (0.150 g, 26%); mp 110–111 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.87 (t, $J=7.2$ Hz, 3H, CH_3), 1.75 (brs, 1H, NH), 2.27 (s, 1H, CH_3), 3.56 (dd, 1H, $J=2.1, 1.2$ Hz, H-5), 3.78–3.99 (m, 2H, CH_2), 4.45 (d, $J=2.1$ Hz, 1H, H-6), 4.94 (s, 1H, H-2), 6.09 (brs, 1H, OH), 6.84–7.34 (m, 12H, aromatic). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 14.3, 21.5, 58.6, 59.0, 59.2, 59.4, 96.2, 115.1, 115.2, 115.3, 115.4, 129.3, 129.4, 129.9, 130.0, 130.2, 132.1, 133.6, 135.9, 136.0, 138.6, 142.1, 142.2, 160.6, 160.9, 163.9, 164.2, 157.4, 169.2. IR (KBr) $\nu_{\max}$: 735, 1236, 1268, 1532, 1603, 1669, 2991, 3310, 3447 cm^{-1} ; *Anal.* Calcd for $\text{C}_{27}\text{H}_{25}\text{F}_2\text{NO}_3\text{S}$: C, 67.34; H, 5.23; N, 2.91. Found: C, 67.39; H, 5.18; N, 2.97.

Ethyl 4-Hydroxy-2,6-di(4-methylphenyl)-5-[(4-methylphenyl)sulfanyl]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**2t**): Isolated as colorless crystals; (0.282 g, 50%); mp 137–138 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.95 (t, $J=7.2$ Hz, 3H, CH_3), 2.27 (s, 1H, CH_3), 2.33 (s, 1H, CH_3), 2.42 (s, 1H, CH_3), 3.72 (d, $J=10.0$ Hz, 1H, H-5), 3.76 (d, $J=10.0$ Hz, 1H, H-6), 3.74–4.03 (m, 2H, CH_2), 4.91 (s, 1H, H-2), 6.64–7.37 (m, 12H, aromatic). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 14.6, 21.5, 21.6, 21.7, 53.8, 55.6, 56.6, 59.4, 96.6, 127.1, 127.8, 128.4, 128.8, 129.6, 130.4, 135.9, 136.0, 138.1, 139.3, 139.5, 141.7, 155.6, 168.8. IR (KBr) $\nu_{\max}$: 741, 1235, 1261, 1534, 1607, 1665, 2993, 3312, 3441 cm^{-1} ; *Anal.* Calcd for $\text{C}_{29}\text{H}_{31}\text{NO}_3\text{S}$: C, 73.54; H, 6.60; N, 2.96. Found: C, 73.50; H, 6.67; N, 2.91.

Ethyl 4-Hydroxy-2,6-di(4-methylphenyl)-5-[(4-methylphenyl)sulfanyl]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**3t**): Isolated as colorless crystals; (0.045 g, 8%); mp 120–120 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.84 (t, $J=7.2$ Hz, 3H, CH_3), 1.79 (brs, 1H, NH), 2.25 (s, 1H, CH_3), 2.32 (s, 1H, CH_3), 2.45 (s, 1H, CH_3), 3.54 (dd, 1H, $J=2.0, 1.2$ Hz, H-5), 3.77–4.00 (m, 2H, CH_2), 4.43 (d, $J=2.0$ Hz, 1H, H-6), 4.90 (s, 1H, H-2), 6.04 (brs, 1H, OH), 6.75–7.43 (m, 12H, aromatic). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 14.2, 21.3, 21.6, 21.9, 58.5, 58.9, 59.0, 59.1, 96.3, 127.5, 127.9, 128.3, 128.5, 129.7, 130.2, 135.7, 136.5, 138.6, 139.1, 139.2, 141.8, 157.2, 169.5. IR (KBr) $\nu_{\max}$: 737, 1230, 1259, 1538, 1602, 1662, 2984, 3305, 3452 cm^{-1} ; *Anal.* Calcd for $\text{C}_{29}\text{H}_{31}\text{NO}_3\text{S}$: C, 73.54; H, 6.60; N, 2.96. Found: C, 73.59; H, 6.56; N, 2.92.

Ethyl 2,6-Di(2-chlorophenyl)-4-hydroxy-5-[(4-methylphenyl)sulfanyl]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**3u**): Isolated as colorless crystals; (0.305 g, 50%); mp 133–134 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.83 (t, $J=7.2$ Hz, 3H, CH_3), 1.88 (brs, 1H, NH), 2.25 (s, 1H, CH_3), 3.70–4.20 (m, 3H, CH_2 and H-5), 4.70–4.89 (m, 1H, H-6), 5.54 (s, 1H, H-2), 6.19 (brs, 1H, OH), 6.83 (d, $J=7.8$ Hz, 2H, aromatic), 6.92 (d, $J=7.8$ Hz, 2H, aromatic), 7.10–7.55 (m, 8H, aromatic). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 13.6, 21.0, 54.6, 55.0, 56.4, 59.0, 95.0, 126.5, 127.1, 127.8, 128.6, 128.8, 128.9, 129.4, 129.7, 130.0, 131.9, 132.4, 132.7, 133.7, 137.1, 137.7, 143.5, 157.5, 168.6. IR (KBr) $\nu_{\max}$: 746, 1227, 1261, 1521, 1610, 1664, 2985, 3315, 3442 cm^{-1} ; *Anal.* Calcd for $\text{C}_{27}\text{H}_{25}\text{Cl}_2\text{NO}_3\text{S}$: C, 63.03; H, 4.90; N, 2.72. Found: C, 63.08; H, 4.97; N, 2.65.

Ethyl 2,6-Di(2,4-dichlorophenyl)-4-hydroxy-5-[(4-methylphenyl)sulfanyl]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**3v**): Isolated as pale yellow solid;

(0.312 g, 45%); mp 141–142 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.95 (t, $J=7.2$ Hz, 3H, CH_3), 1.87 (brs, 1H, NH), 2.27 (s, 3H, CH_3), 3.94–4.03 (m, 2H, CH_2), 4.06 (s, 1H, H-5), 4.72 (s, 1H, H-6), 5.43 (s, 1H, H-2), 6.89–6.95 (m, 4H, aromatic), 7.15 (d, $J=2.1$ Hz, 1H), 7.22–7.29 (m, 3H, aromatic), 7.38 (d, $J=1.8$ Hz, 1H), 7.47 (d, $J=8.4$ Hz, 1H), 12.3 (s, 1H, OH). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 13.5, 21.1, 53.1, 56.2, 59.0, 60.7, 100.5, 126.7, 127.7, 128.5, 128.7, 129.0, 129.5, 130.7, 131.2, 132.5, 133.0, 133.3, 134.0, 134.4, 135.0, 137.7, 140.3, 170.5, 170.9. IR (KBr) $\nu_{\max}$: 743, 1228, 1265, 1520, 1614, 1667, 2988, 3318, 3446 cm^{-1} ; *Anal.* Calcd for $\text{C}_{27}\text{H}_{23}\text{Cl}_4\text{NO}_3\text{S}$: C, 55.59; H, 3.97; N, 2.40. Found: C, 55.55; H, 3.91; N, 2.48.

Ethyl 4-Hydroxy-5-[(4-methylphenyl)sulfanyl]-2,6-di(3-nitrophenyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (**2w** and **3w**) (Appears as Mixture in a Ratio 1:0.30): Isolated as viscous liquid; (0.293 g, 46%); $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.83–1.01 (m, CH_3), 2.23 (s, CH_3), 2.27 (s, CH_3), 3.86–4.21 (m, CH_2), 4.58–5.10 (m, H-5, H-6, H-2), 6.91–8.48 (m, aromatic), 12.3 (s, OH), 12.8 (s, OH). HR-MS (ESI) m/z : Calcd for $\text{C}_{27}\text{H}_{23}\text{N}_3\text{O}_7\text{S}$: 535.1413; Found, 534.2901 (M–1).

Synthesis of Ethyl 4-Hydroxy-2,6-diaryl-5-(arylsulfanyl)-3-pyridinecarboxylates (5). General Procedure To a solution of ethyl 4-hydroxy-2,6-diaryl-5-(arylsulfanyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (1 mmol) in benzene (20 ml), dichloro-dicyanobenzoquinone (2 mmol) was added and refluxed over a water bath for 30 min. The precipitated DDQ-H₂ was filtered off and the filtrate evaporated under vacuum. The residue was crystallized from ethanol to give the product.

Ethyl 4-Hydroxy-2,6-diphenyl-5-(phenylsulfanyl)-3-pyridinecarboxylate (**5a**): Isolated as colorless crystals (0.072 g, 73%); mp 148–149 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.78 (t, $J=7.2$ Hz, 3H, CH_3), 3.98 (q, $J=7.2$ Hz, 2H, CH_2), 6.57 (brs, 1H, OH), 7.06–7.57 (m, 15H, aromatic). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 13.6, 61.5, 108.2, 108.7, 126.2, 126.5, 128.0, 128.4, 128.8, 128.9, 129.0, 129.6, 129.7, 135.8, 140.8, 142.3, 156.5, 161.5, 165.2, 169.6. IR (KBr) $\nu_{\max}$: 732, 1020, 1099, 1245, 1480, 1536, 1585, 1679, 2971, 3355 cm^{-1} ; *Anal.* Calcd for $\text{C}_{26}\text{H}_{21}\text{NO}_3\text{S}$: C, 73.04; H, 4.95; N, 3.28. Found: C, 73.10; H, 4.99; N, 3.22.

Ethyl 2,6-Di(4-chlorophenyl)-4-hydroxy-5-(phenylsulfanyl)-3-pyridinecarboxylate (**5b**): Isolated as colorless crystals (0.083 g, 84%); mp 115–116 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.87 (t, $J=7.2$ Hz, 3H, CH_3), 4.02 (q, $J=7.2$ Hz, 2H, CH_2), 6.65 (brs, 1H, OH), 6.65–7.50 (m, 13H, aromatic). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 13.8, 61.6, 108.0, 109.0, 126.5, 128.2, 128.6, 129.8, 130.2, 131.0, 135.1, 135.2, 135.3, 139.0, 140.6, 142.3, 156.7, 160.4, 164.0, 169.2. IR (KBr) $\nu_{\max}$: 738, 1012, 1083, 1238, 1486, 1525, 1587, 1683, 2985, 3336 cm^{-1} ; *Anal.* Calcd for $\text{C}_{26}\text{H}_{19}\text{Cl}_2\text{NO}_3\text{S}$: C, 62.91; H, 3.86; N, 2.82. Found: C, 62.85; H, 3.80; N, 2.87.

Ethyl 2,6-Di(4-fluorophenyl)-4-hydroxy-5-(phenylsulfanyl)-3-pyridinecarboxylate (**5c**): Isolated as colorless crystals; (0.074 g, 75%); mp 117–118 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.87 (t, $J=7.2$ Hz, 3H, CH_3), 4.02 (q, $J=7.2$ Hz, 2H, CH_2), 6.62 (brs, 1H, OH), 6.62–7.56 (m, 13H, aromatic). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 13.7, 61.6, 108.1, 108.8, 114.9, 115.1, 115.2, 115.5, 126.4, 126.5, 129.8, 130.7, 130.8, 131.5, 131.6, 135.5, 136.6, 138.3, 156.7, 160.3, 161.8, 161.9, 164.1, 165.1, 165.2, 169.4. IR (KBr) $\nu_{\max}$: 735, 1015, 1080, 1239, 1480, 1533, 1592, 1681, 2989, 3339 cm^{-1} ; *Anal.* Calcd for $\text{C}_{26}\text{H}_{19}\text{F}_2\text{NO}_3\text{S}$: C, 67.37; H, 4.13; N, 3.02. Found: C, 67.41; H, 4.08; N, 3.09.

Ethyl 4-Hydroxy-2,6-di(4-methylphenyl)-5-(phenylsulfanyl)-3-pyridinecarboxylate (**5d**): Isolated as colorless crystals; (0.071 g, 72%); mp 107–109 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.80 (t, $J=6.6$ Hz, 3H, CH_3), 2.31 (s, 1H, CH_3), 2.35 (s, 1H, CH_3), 3.85 (q, $J=6.6$ Hz, 2H, CH_2), 6.60 (brs, 1H, OH), 6.62–7.56 (m, 13H, aromatic). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 13.6, 21.7, 21.8, 61.5, 108.2, 108.6, 126.3, 126.5, 128.7, 128.9, 129.0, 129.5, 129.7, 135.7, 139.0, 156.6, 161.1, 164.8, 169.5. IR (KBr) $\nu_{\max}$: 739, 1017, 1086, 1237, 1482, 1538, 1590, 1686, 2992, 3341 cm^{-1} ; *Anal.* Calcd for $\text{C}_{28}\text{H}_{25}\text{NO}_3\text{S}$: C, 73.82; H, 5.53; N, 3.07. Found: C, 73.87; H, 5.59; N, 3.00.

Ethyl 2,6-Di(2-chlorophenyl)-4-hydroxy-5-(phenylsulfanyl)-3-pyridinecarboxylate (**5e**): Isolated as colorless crystals; (0.076 g, 77%); mp 135–136 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.79 (t, $J=7.2$ Hz, 3H, CH_3), 3.92–4.31 (m, 2H, CH_2), 6.62–7.56 (m, 13H, aromatic). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ_{C} : 13.5, 61.5, 108.9, 112.2, 126.6, 127.2, 127.3, 129.0, 129.3, 129.4, 129.6, 129.7, 129.9, 130.7, 132.2, 132.8, 133.1, 134.7, 139.6, 141.9, 156.7, 159.6, 163.9, 168.3. IR (KBr) $\nu_{\max}$: 734, 1013, 1083, 1240, 1479, 1531, 1593, 1682, 2990, 3347 cm^{-1} ; *Anal.* Calcd for $\text{C}_{26}\text{H}_{19}\text{Cl}_2\text{NO}_3\text{S}$: C, 62.91; H, 3.86; N, 2.82. Found: C, 62.95; H, 3.80; N, 2.75.

Ethyl 2,6-Di(2-bromophenyl)-4-hydroxy-5-(phenylsulfanyl)-3-pyridinecarboxylate (**5f**): Isolated as solid (0.071 g, 72%); mp 103–104 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ_{H} : 0.83 (t, $J=6.9$ Hz, 3H, CH_3), 3.80–4.31 (m, 2H,

CH₂), 7.16–7.59 (m, 14H, OH and aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 12.9, 62.5, 110.0, 121.9, 122.3, 126.5, 126.9, 127.2, 127.9, 128.3, 128.9, 129.3, 129.7, 130.2, 131.9, 132.1, 132.5, 134.8, 135.3, 141.1, 149.9, 159.3, 163.6, 169.4. IR (KBr) ν_{max}: 732, 1016, 1081, 1245, 1480, 1535, 1590, 1684, 2992, 3345 cm⁻¹; *Anal.* Calcd for C₂₆H₁₉Br₂NO₃S: C, 53.35; H, 3.27; N, 2.39. Found: C, 53.30; H, 3.34; N, 2.31.

Ethyl 2,6-Di(2,4-dichlorophenyl)-4-hydroxy-5-(phenylsulfanyl)-3-pyridinecarboxylate (**5g**): Isolated as solid (0.080 g, 82%); mp 83–84 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.93 (t, *J* = 7.2 Hz, 3H, CH₃), 3.99–4.14 (m, 2H, CH₂), 7.05–7.43 (m, 12H, OH and aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 13.0, 62.7, 110.0, 119.0, 126.6, 126.8, 127.1, 127.9, 128.7, 128.9, 129.3, 132.0, 133.1, 133.6, 134.2, 134.7, 134.9, 135.2, 136.5, 138.5, 157.5, 163.2, 169.5. IR (KBr) ν_{max}: 736, 1015, 1084, 1243, 1478, 1534, 1594, 1680, 2988, 3343 cm⁻¹; *Anal.* Calcd for C₂₆H₁₇Cl₄NO₃S: C, 55.24; H, 3.03; N, 2.48. Found: C, 55.32; H, 2.97; N, 2.55.

Ethyl 4-Hydroxy-2,6-di(3-nitrophenyl)-5-(phenylsulfanyl)-3-pyridinecarboxylate (**5h**): Isolated as solid (0.074 g, 75%); mp 75–76 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.91 (t, *J* = 7.2 Hz, 3H, CH₃), 4.17 (q, *J* = 7.2 Hz, 2H, CH₂), 7.07–7.66 (m, 5H, OH and aromatic), 7.85–8.48 (m, 9H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 13.2, 62.7, 109.0, 118.0, 123.5, 123.8, 123.9, 124.7, 126.7, 128.1, 128.3, 128.8, 129.0, 129.2, 134.6, 134.8, 135.4, 140.2, 142.3, 147.8, 159.0, 164.2, 169.2. IR (KBr) ν_{max}: 735, 1016, 1085, 1246, 1360, 1481, 1535, 1590, 1683, 2991, 3346 cm⁻¹; *Anal.* Calcd for C₂₆H₁₉N₃O₇S: C, 60.34; H, 3.70; N, 8.12. Found: C, 60.26; H, 3.76; N, 8.05.

Ethyl 5-[(4-Chlorophenyl)sulfanyl]-4-hydroxy-2,6-diphenyl-3-pyridinecarboxylate (**5i**): Isolated as colorless crystals; (0.075 g, 76%); mp 92–93 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.79 (t, *J* = 7.2 Hz, 3H, CH₃), 3.99 (q, *J* = 7.2 Hz, 2H, CH₂), 6.58 (brs, 1H, OH), 6.96–7.58 (m, 14H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 13.5, 61.5, 108.4, 108.5, 127.9, 128.1, 128.4, 128.9, 129.0, 129.1, 129.5, 129.8, 132.2, 134.3, 142.0, 156.4, 160.4, 165.2, 169.5. IR (KBr) ν_{max}: 735, 1025, 1095, 1248, 1486, 1541, 1589, 1689, 2978, 3351 cm⁻¹; *Anal.* Calcd for C₂₆H₂₀ClNO₃S: C, 67.60; H, 4.36; N, 3.03. Found: C, 67.68; H, 4.29; N, 2.97.

Ethyl 2,6-Di(4-chlorophenyl)-5-[(4-chlorophenyl)sulfanyl]-4-hydroxy-3-pyridinecarboxylate (**5j**): Isolated as colorless crystals; (0.086 g, 87%); mp 125–126 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.88 (t, *J* = 7.2 Hz, 3H, CH₃), 4.03 (q, *J* = 7.2 Hz, 2H, CH₂), 6.65 (brs, 1H, OH), 6.94–7.50 (m, 12H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 13.7, 61.7, 108.2, 108.7, 127.8, 128.3, 128.6, 129.9, 130.3, 130.9, 132.5, 133.8, 135.2, 135.3, 138.7, 140.4, 156.7, 160.5, 164.0, 169.1. IR (KBr) ν_{max}: 730, 1029, 1092, 1243, 1484, 1532, 1594, 1696, 2995, 3347 cm⁻¹; *Anal.* Calcd for C₂₆H₁₈Cl₃NO₃S: C, 58.83; H, 3.42; N, 2.64. Found: C, 58.89; H, 3.46; N, 2.69.

Ethyl 5-[(4-Chlorophenyl)sulfanyl]-2,6-di(4-fluorophenyl)-4-hydroxy-3-pyridinecarboxylate (**5k**): Isolated as colorless crystals; (0.077 g, 78%); mp 109–110 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.88 (t, *J* = 6.9 Hz, 3H, CH₃), 4.03 (q, *J* = 6.9 Hz, 2H, CH₂), 6.61 (brs, 1H, OH), 6.95–7.57 (m, 12H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 13.7, 61.6, 108.2, 108.4, 114.9, 115.2, 115.5, 127.8, 128.7, 129.9, 130.7, 130.8, 131.4, 131.6, 132.4, 134.0, 136.5, 138.2, 156.6, 160.5, 162.0, 164.1, 165.1, 166.3, 169.3. IR (KBr) ν_{max}: 742, 1038, 1085, 1254, 1491, 1540, 1598, 1690, 2991, 3340 cm⁻¹; *Anal.* Calcd for C₂₆H₁₈ClF₂NO₃S: C, 62.71; H, 3.64; N, 2.81. Found: C, 62.65; H, 3.60; N, 2.87.

Ethyl 5-[(4-Chlorophenyl)sulfanyl]-4-hydroxy-2,6-di(4-methylphenyl)-3-pyridinecarboxylate (**5l**): Isolated as colorless crystals; (0.071 g, 72%); mp 105–106 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.78 (t, *J* = 6.9 Hz, 3H, CH₃), 2.31 (s, 1H, CH₃), 2.35 (s, 1H, CH₃), 3.99 (q, *J* = 6.9 Hz, 2H, CH₂), 6.87–7.61 (m, 12H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 13.5, 21.7, 21.8, 62.0, 108.6, 112.2, 126.6, 127.2, 128.1, 128.9, 129.0, 129.1, 129.4, 130.0, 132.7, 133.2, 140.0, 157.3, 160.4, 165.2, 168.5. IR (KBr) ν_{max}: 731, 1046, 1081, 1250, 1487, 1549, 1592, 1696, 2995, 3350 cm⁻¹; *Anal.* Calcd for C₂₈H₂₄ClNO₃S: C, 68.63; H, 4.94; N, 2.86. Found: C, 68.59; H, 4.88; N, 2.90.

Ethyl 2,6-Di(2-chlorophenyl)-5-[(4-chlorophenyl)sulfanyl]-4-hydroxy-3-pyridinecarboxylate (**5m**): Isolated as colorless crystals; (0.079 g, 80%); mp 112–113 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.85 (t, *J* = 7.2 Hz, 3H, CH₃), 3.94–4.25 (m, 2H, CH₂), 6.95–7.49 (m, 12H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 13.6, 61.7, 108.7, 112.8, 126.9, 127.4, 127.6, 128.9, 129.2, 129.5, 129.7, 129.9, 130.1, 130.6, 132.2, 132.7, 133.2, 134.5, 139.7, 141.7, 156.2, 159.2, 163.8, 168.5. IR (KBr) ν_{max}: 738, 1041, 1097, 1263, 1495, 1542, 1581, 1690, 2998, 3353 cm⁻¹; *Anal.* Calcd for C₂₆H₁₈Cl₃NO₃S: C, 58.83; H, 3.42; N, 2.64. Found: C, 58.88; H, 3.37; N, 2.59.

Ethyl 2,6-Di(2-bromophenyl)-5-[(4-chlorophenyl)sulfanyl]-3-pyridinecarboxylate (**5n**): Isolated as solid (0.069 g, 70%); mp 77–78 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.84 (t, *J* = 7.2 Hz, 3H, CH₃), 4.00–4.28 (m, 2H,

CH₂), 6.98–7.61 (m, 13H, OH and aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 12.9, 62.5, 110.0, 121.9, 122.4, 126.5, 126.9, 127.2, 127.9, 128.3, 128.9, 129.3, 129.7, 130.2, 131.9, 132.1, 132.5, 134.8, 135.3, 141.1, 143.1, 149.9, 159.4, 169.5. IR (KBr) ν_{max}: 736, 1043, 1096, 1265, 1497, 1540, 1582, 1688, 2997, 3351 cm⁻¹; *Anal.* Calcd for C₂₆H₁₈Br₂ClNO₃S: C, 50.39; H, 2.93; N, 2.26. Found: C, 50.45; H, 2.99; N, 2.18.

Ethyl 5-[(4-Chlorophenyl)sulfanyl]-2,6-di(2,4-dichlorophenyl)-3-pyridinecarboxylate (**5o**): Isolated as solids (0.078 g, 79%); mp 109–110 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.93 (t, *J* = 7.2 Hz, 3H, CH₃), 4.09–4.26 (m, 2H, CH₂), 7.04–7.43 (m, 11H, OH and aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 13.0, 62.8, 110.0, 118.5, 126.9, 127.1, 128.3, 128.6, 129.0, 129.4, 130.2, 130.5, 132.6, 133.0, 133.2, 133.6, 134.8, 135.3, 136.5, 138.5, 157.0, 163.3, 168.8, 169.5. IR (KBr) ν_{max}: 737, 1044, 1098, 1260, 1496, 1545, 1579, 1691, 2995, 3356 cm⁻¹; *Anal.* Calcd for C₂₆H₁₆Cl₅NO₃S: C, 52.07; H, 2.69; N, 2.34. Found: C, 52.15; H, 2.62; N, 2.41.

Ethyl 4-Hydroxy-5-[(4-methylphenyl)sulfanyl]-2,6-diphenyl-3-pyridinecarboxylate (**5p**): Isolated as colorless crystals; (0.069 g, 70%); mp 95–96 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.77 (t, *J* = 6.9 Hz, 3H, CH₃), 2.30 (s, 1H, CH₃), 3.97 (q, *J* = 6.9 Hz, 2H, CH₂), 6.95–7.54 (m, 14H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 13.5, 21.4, 61.9, 108.5, 111.3, 126.6, 127.4, 128.2, 128.5, 129.0, 129.7, 130.9, 137.0, 137.7, 139.2, 157.3, 160.4, 165.2, 168.5. IR (KBr) ν_{max}: 748, 1056, 1091, 1260, 1499, 1553, 1587, 1681, 2987, 3357 cm⁻¹; *Anal.* Calcd for C₂₇H₂₃NO₃S: C, 73.44; H, 5.25; N, 3.17. Found: C, 73.49; H, 5.31; N, 3.23.

Ethyl 2,6-Di(4-chlorophenyl)-4-hydroxy-5-[(4-methylphenyl)sulfanyl]-3-pyridinecarboxylate (**5q**): Isolated as colorless crystals; (0.078 g, 79%); mp 119–120 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.87 (t, *J* = 7.2 Hz, 3H, CH₃), 2.29 (s, 1H, CH₃), 4.01 (q, *J* = 7.2 Hz, 2H, CH₂), 6.66 (brs, 1H, OH), 6.93–7.51 (m, 12H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 13.7, 21.3, 61.6, 108.1, 109.7, 126.8, 128.5, 130.3, 130.6, 131.1, 131.6, 135.0, 135.2, 136.5, 138.9, 140.6, 156.7, 160.2, 163.8, 169.2. IR (KBr) ν_{max}: 742, 1051, 1084, 1267, 1506, 1559, 1582, 1678, 2993, 3349 cm⁻¹; *Anal.* Calcd for C₂₇H₂₁Cl₂NO₃S: C, 63.53; H, 4.15; N, 2.74. Found: C, 63.59; H, 4.11; N, 2.68.

Ethyl 2,6-Di(4-fluorophenyl)-4-hydroxy-5-[(4-methylphenyl)sulfanyl]-3-pyridinecarboxylate (**5r**): Isolated as colorless crystals; (0.071 g, 72%); mp 107–108 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.87 (t, *J* = 7.2 Hz, 3H, CH₃), 2.29 (s, 1H, CH₃), 4.01 (q, *J* = 7.2 Hz, 2H, CH₂), 6.63 (brs, 1H, OH), 6.93–7.57 (m, 12H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 13.7, 21.3, 61.5, 108.1, 109.4, 114.8, 115.1, 115.5, 115.5, 126.8, 130.5, 130.7, 130.8, 131.5, 131.6, 131.7, 136.5, 136.6, 138.2, 156.6, 160.2, 161.9, 164.9, 169.3. IR (KBr) ν_{max}: 740, 1056, 1079, 1260, 1502, 1568, 1589, 1681, 2988, 3341 cm⁻¹; *Anal.* Calcd for C₂₇H₂₁F₂NO₃S: C, 67.91; H, 4.43; N, 2.93. Found: C, 67.98; H, 4.49; N, 2.89.

Ethyl 4-Hydroxy-2,6-di(4-methylphenyl)-5-[(4-methylphenyl)sulfanyl]-3-pyridinecarboxylate (**5s**): Isolated as viscous liquid; (0.069 g, 70%); ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.80 (t, *J* = 6.6 Hz, 3H, CH₃), 2.26 (s, 1H, CH₃), 2.30 (s, 1H, CH₃), 2.35 (s, 1H, CH₃), 3.97 (q, *J* = 6.6 Hz, 2H, CH₂), 6.54 (brs, 1H, OH), 6.94–7.46 (m, 12H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 13.7, 21.4, 21.7, 21.8, 61.5, 108.2, 109.0, 126.7, 128.7, 128.9, 129.0, 129.6, 130.5, 132.2, 136.2, 137.6, 138.8, 138.9, 139.0, 156.5, 161.1, 164.9, 169.7. IR (CHCl₃) ν_{max}: 745, 1052, 1082, 1268, 1513, 1561, 1582, 1676, 2980, 3357 cm⁻¹; *Anal.* Calcd for C₂₉H₂₇NO₃S: C, 74.17; H, 5.80; N, 2.98. Found: C, 74.23; H, 5.86; N, 2.91.

Ethyl 2,6-Di(2-chlorophenyl)-4-hydroxy-5-[(4-methylphenyl)sulfanyl]-3-pyridinecarboxylate (**5t**): Isolated as colorless crystals; (0.073 g, 74%); mp 98–99 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.84 (t, *J* = 7.2 Hz, 3H, CH₃), 2.28 (s, 1H, CH₃), 3.91–4.20 (m, 2H, CH₂), 6.77–7.80 (m, 12H, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 13.5, 21.3, 61.8, 108.5, 112.6, 126.7, 127.2, 127.4, 128.7, 129.0, 129.3, 129.5, 129.7, 130.0, 130.4, 132.0, 132.5, 133.0, 134.3, 139.6, 141.6, 156.3, 159.0, 163.6, 169.4. IR (KBr) ν_{max}: 749, 1058, 1076, 1271, 1507, 1565, 1589, 1681, 2973, 3348 cm⁻¹; *Anal.* Calcd for C₂₇H₂₁Cl₂NO₃S: C, 63.53; H, 4.15; N, 2.74. Found: C, 63.48; H, 4.21; N, 2.80.

Ethyl 2,6-Di(2,4-dichlorophenyl)-4-hydroxy-5-[(4-methylphenyl)sulfanyl]-3-pyridinecarboxylate (**5u**): Isolated as solid (0.080 g, 81%); mp 76–77 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.92 (t, *J* = 7.2 Hz, 3H, CH₃), 2.23 (s, 3H, CH₃), 3.94–4.14 (m, 2H, CH₂), 7.03–7.49 (m, 11H, OH, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_c: 13.0, 21.0, 62.6, 110.0, 119.2, 126.8, 127.0, 128.3, 128.6, 129.3, 129.4, 129.7, 130.0, 130.7, 131.0, 132.5, 133.1, 134.8, 135.1, 136.7, 138.7, 157.0, 163.1, 168.8, 169.5. IR (KBr) ν_{max}: 745, 1057, 1078, 1270, 1508, 1562, 1590, 1685, 2976, 3346 cm⁻¹; *Anal.* Calcd for C₂₇H₁₉Cl₄NO₃S: C, 55.98; H, 3.31; N, 2.42. Found: C, 55.92; H, 3.25; N,

2.48.

Ethyl 4-Hydroxy-5-[(4-methylphenyl)sulfanyl]-2,6-di-(3-nitrophenyl)-3-pyridine-carboxylate (**5v**): Isolated as solid (0.077 g, 78%); mp 120–121 °C; ¹H-NMR (300 MHz, CDCl₃) δ_H: 0.91 (t, *J*=7.2 Hz, 3H, CH₃), 2.28 (s, 3H, CH₃), 4.17 (q, *J*=7.2 Hz, 2H, CH₂), 6.91–8.52 (m, 13H, OH, aromatic). ¹³C-NMR (75 MHz, CDCl₃) δ_C: 13.2, 20.9, 62.6, 109.3, 117.5, 123.8, 124.7, 127.3, 128.3, 128.7, 129.0, 129.9, 130.3, 130.5, 131.1, 134.6, 135.4, 136.9, 140.3, 142.2, 147.7, 158.5, 162.5, 168.9, 169.3. IR (KBr) ν_{max}: 733, 1019, 1084, 1245, 1357, 1483, 1539, 1592, 1688, 2994, 3347 cm⁻¹; *Anal.* Calcd for C₂₇H₂₁N₃O₇S: C, 61.01; H, 3.98; N, 7.91. Found: C, 61.07; H, 3.95; N, 7.98.

In-Vitro Antimycobacterial Activity All compounds were screened for their *in vitro* anti-mycobacterial activity against MTB, in Middlebrook 7H11 agar medium supplemented with OADC by agar dilution method similar to that recommended by the National Committee for Clinical Laboratory Standards for the determination of MIC in triplicate.⁵¹ The MIC is defined as the minimum concentration of compound required to give complete inhibition of bacterial growth.

Acknowledgements S.P. thanks the Department of Science and Technology, New Delhi, for funding for a major research project (No. SR/S1/OC-70/2006) and for funds under (i) IRHPA program for funds for the purchase of a high resolution NMR spectrometer and (ii) FIST program and the University Grants Commission, New Delhi, for (i) funds under the DRS and ASIST programs and (ii) for funding for a major research project [F. No. 36-155/2008(SR)]. RSK thanks CSIR, New Delhi for Senior Research Fellowship and SMR thanks UGC, New Delhi for Junior Research Fellowship.

References and Notes

- Tawara J. N., Lorenz P., Stermitz F. R., *J. Nat. Prod.*, **62**, 321–323 (1999).
- Watson P. S., Jiang B., Scott B., *Org. Lett.*, **2**, 3679–3681 (2000).
- Brooks C. A., Comins D. L., *Tetrahedron Lett.*, **41**, 3551–3553 (2000).
- Mukhtar T. A., Wright G. D., *Chem. Rev.*, **105**, 529–542 (2005).
- Richardo G. J., Juan B. C., Mario R. A., Rolder M., Peinado C. R., *Fernando. Spen.*, **47**, 168–172 (1979).
- Jerom B. R., Spencer K. H., *Eur. Pat. Appl. EP 277794* (1998).
- Perumal R. V., Adiraj M., Shanmugapandian P., *Indian Drugs*, **38**, 156–159 (2001).
- Ganellin C. R., Spickett, R. G., *J. Med. Chem.*, **8**, 619–625 (1965).
- Hangenbach R. E., Gysin H., *Experientia*, **8**, 184–185 (1952).
- Heana B., Dobre V., Niculesar-Duvaz I., *J. Prakt. Chem.*, **327**, 667–674 (1985).
- Mobio I. G., Soldatenkov A. T., Federov V. O., Ageer E. A., Sergeeva N. D., Lin S., Stashenko E. E., Prostakov N. S., Andreeva E. I., *Khim. Farm. Zh.*, **23**, 421–427 (1989).
- Angle S. R., Breitenbucher J. G., “Natural Products Chemistry: Stereoselective Synthesis. Atta-ur-Rahman,” 16th ed., Part I, Elsevier, New York, 1995, pp. 453–502.
- Grishina G. V., Gaidorova E. L., Zefirov N. S., *Chem. Heterocycl. Compd.*, **30**, 1401–1426 (1994).
- Wang C. L., Wuorola M. A., *Org. Prep. Proceed. Int.*, **24**, 585–621 (1992).
- Fleet G. W. J., Ramsden N. G., Witty D. R., *Tetrahedron*, **45**, 319–326 (1990).
- Winkler D. A., Holan G., *J. Med. Chem.*, **32**, 2084–2089 (1989).
- Fleet G. W. J., Ramsden N. G., Dwek R. A., Rademacher T. W., Nash R. J., Green D. S. C., Winchester B., *J. Chem. Soc. Chem. Commun.*, **7**, 483–485 (1988).
- Beeler A. B., Gadepalli R. S. V. S., Steyn S., Castagnoli N., Rimoldi J. M., *Bioorg. Med. Chem.*, **11**, 5229–5234 (2003).
- Deskus J. A., Epperson J. R., Charles P. S., Joseph A. C., Dextraze P., Qian-Cutrone J., Gao Q., Ma B., Beno B. R., Mattson G. K., Molski T. F., Krause R. G., Taber M. T., Lodge N. J., Mattson R. J., *Bioorg. Med. Chem. Lett.*, **17**, 3099–3104 (2007).
- Gwaltney S. L., O'Connor S. J., Nelson L. T. J., Sullivan G. M., Imade H., Wang W., Hasvold L., Li Q., Cohen J., Gu W.-Z., Tahir S. K., Bauch J., Marsh K., Ng S.-C., Frost D. J., Zhang H., Muchmore S., Jakob C. G., Stoll V., Hutchins C., *Bioorg. Med. Chem. Lett.*, **13**, 1359–1362 (2003).
- Kamei K., Maeda N., Katsuragi-Ogino R., Koyama M., Nakajima M., Tatsuoka T., Ohno T., Inoue T., *Bioorg. Med. Chem. Lett.*, **15**, 2990–2993 (2005).
- Hisaki M., Kashima K., Sakamoto Y., Hojo M., Katayama O., Hata H., *Eur. Pat. Appl. EP 220653* (1987).
- Attia A., Michael M., *Pharmazie*, **37**, 551–553 (1982).
- Quintela J. M., Peinador C., Botana L., Estevez M., Riguera R., *Bioorg. Med. Chem.*, **5**, 1543–1553 (1997).
- Zhu G. D., Arendsen D. L., Gunawardana I. W., Boyd S. A., Stewart A. O., Fry D. G., Cool B. L., Kifle L., Schaefer V., Meuth J., Marsh K. C., Kempf-Grote A. J., Kilgannon P., Gallatin W. M., Okasinski G. F., *J. Med. Chem.*, **44**, 3469–3487 (2001).
- Roth H. J., Kleeman A., “Pharmaceutical Chemistry,” John Wiley & Sons, New York, 1988.
- Bashford K. E., Burton M. B., Cameron S., Cooper A. L., Hogg R. D., Kane P. D., MacManus D. A., Matrunola C. A., Moody C. J., Robertson A. A. B., Warne M. R., *Tetrahedron Lett.*, **44**, 1627–1629 (2003).
- Raw S. A., Taylor R. J. K., *Chem. Commun.*, **2004**, 508–509 (2004).
- Constable E. C., Housecroft C. E., Neuburger M., Phillips D., Raithby P. R., Schofield E., Sparr E., Tocher D. A., Zehnder M., Zimmermann Y., *J. Chem. Soc. Dalton Trans.*, **2000**, 2219–2228 (2000).
- Cave G. W. V., Hardie M. J., Roberts B. A., Raston C. L., *Eur. J. Org. Chem.*, **2001**, 3227–3231 (2001).
- Cutshall N. S., Kucera K. A., Ursion R., Latham J., Ihle N. C., *Bioorg. Med. Chem. Lett.*, **12**, 1517–1520 (2002).
- Comins D. L., Smith E. D., *Tetrahedron Lett.*, **47**, 1449–1451 (2006).
- http://www.who.int/mediacentre/news/releases/2009/tuberculosis_report_20090324/en/index.html.
- Janin Y. L., *Bioorg. Med. Chem.*, **15**, 2479–2513 (2007).
- Gutierrez-Lugo M. T., Bewley C. A., *J. Med. Chem.*, **51**, 2606–2612 (2008).
- O'Brien R. J., Nunn P. P., *Am. J. Respir. Crit. Care Med.*, **163**, 1055–1058 (2001).
- Ranjith Kumar R., Perumal S., Senthilkumar P., Yogeeswari P., Sriram D., *J. Med. Chem.*, **51**, 5731–5735 (2008).
- Ranjith Kumar R., Perumal S., Senthilkumar P., Yogeeswari P., Sriram D., *Tetrahedron*, **64**, 2962–2971 (2008).
- Ranjith Kumar R., Perumal S., Senthilkumar P., Yogeeswari P., Sriram D., *Bioorg. Med. Chem. Lett.*, **17**, 6459–6462 (2007).
- Karthikeyan S. V., Perumal S., Krithika A. S., Yogeeswari P., Sriram D., *Bioorg. Med. Chem. Lett.*, **19**, 3006–3009 (2009).
- Ranjith Kumar R., Perumal S., Manju S. C., Bhatt P., Yogeeswari P., Sriram D., *Bioorg. Med. Chem. Lett.*, **19**, 3461–3465 (2009).
- Ranjith Kumar R., Perumal S., Senthilkumar P., Yogeeswari P., Sriram D., *Eur. J. Med. Chem.*, **44**, 3821–3829 (2009).
- Balamurugan K., Perumal S., Reddy, A. S. K., Yogeeswari P., Sriram D., *Tetrahedron Lett.*, **50**, 6191–6195 (2009).
- Noller C. R., Baliah V., *J. Am. Chem. Soc.*, **70**, 3853–3855 (1948).
- Shimada K., Kaburagi Y., Fukuyama T., *J. Am. Chem. Soc.*, **125**, 4048–4049 (2003).
- Suresh J., Suresh Kumar R., Perumal S., Natarajan S., *Acta Cryst.*, **E63**, o777–o779 (2007).
- Suresh J., Suresh Kumar R., Perumal S., Natarajan S., *Acta Cryst.*, **E63**, o1377–o1379 (2007).
- Suresh J., Suresh Kumar R., Perumal S., Natarajan S., *Acta Cryst.*, **E63**, o2140–o2141 (2007).
- Suresh J., Suresh Kumar R., Perumal S., Natarajan S., *Acta Cryst.*, **E63**, o1375–o1376 (2007).
- Suresh J., Suresh Kumar R., Perumal S., Mostad A., Natarajan S., *Acta Cryst.*, **C63**, o141–o144 (2007).
- Ten fold serial dilutions of each test compound/drug were incorporated into Middlebrook 7H11 agar medium with OADC Growth Supplement. Inoculum of *M. tuberculosis* H₃₇Rv were prepared from fresh Middlebrook 7H11 agar slants with OADC Growth Supplement adjusted to 1 mg/ml (wet weight) in Tween 80 (0.05%) saline diluted to 10⁻² to give a concentration of approximately 10⁷ cfu/ml. A 5 μl amount of bacterial suspension was spotted into 7H11 agar tubes containing 10-fold serial dilutions of drugs per milliliter. The tubes were incubated at 37 °C, and final readings were recorded after 28 d. The minimum inhibitory concentration (MIC) is defined as the minimum concentration of compound required to give complete inhibition of bacterial growth.